Kazunori Uenaka
Overview
Explore the profile of Kazunori Uenaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yokokawa Shibata R, Kubota R, Uenaka K, Kaibara A, Wajima T
Drug Metab Pharmacokinet
. 2023 May;
51:100496.
PMID: 37244205
The objectives of this analysis were to characterize the pharmacokinetics of duloxetine in Japanese pediatric patients aged 9-17 years with major depressive disorder (MDD) and to explore potential intrinsic factors...
2.
Nakano M, Nakamura T, Takita Y, Uenaka K, Ando T, Senda M, et al.
Ann Nucl Med
. 2019 May;
33(8):639-645.
PMID: 31140155
No abstract available.
3.
Sakai D, Chung H, Oh D, Park S, Kadowaki S, Kim Y, et al.
Cancer Chemother Pharmacol
. 2017 Oct;
80(6):1197-1207.
PMID: 29071414
Purpose: Mesenchymal-epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics of emibetuzumab, a bivalent monoclonal anti-MET antibody that...
4.
Yoh K, Doi T, Ohmatsu H, Kojima T, Takahashi H, Zenke Y, et al.
Invest New Drugs
. 2016 Jul;
34(5):584-95.
PMID: 27422720
Background MET is a tyrosine kinase receptor involved in the regulation of cell proliferation and migration. Reported here are the phase I dose-escalation results for LY2875358, a monoclonal antibody against...
5.
Iida S, Ogiya D, Abe Y, Taniwaki M, Asou H, Maeda K, et al.
Cancer Sci
. 2016 Jun;
107(9):1281-9.
PMID: 27350068
B-cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti-BAFF monoclonal antibody. This phase 1, multicenter, open-label, nonrandomized, dose-escalation study evaluated...
6.
Doi T, Yoshino T, Shitara K, Matsubara N, Fuse N, Naito Y, et al.
Anticancer Drugs
. 2015 Aug;
26(10):1043-53.
PMID: 26288133
This phase I trial evaluated LY2603618, a selective inhibitor of the DNA damage checkpoint kinase 1, in combination with gemcitabine. Japanese patients with advanced solid tumors were enrolled. All patients...
7.
Yamamoto N, Nokihara H, Yamada Y, Uenaka K, Sekiguchi R, Makiuchi T, et al.
Cancer Chemother Pharmacol
. 2013 Apr;
71(6):1645-55.
PMID: 23616084
Purpose: LY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese patients with solid tumors and evaluated pharmacokinetics (PK), pharmacodynamics, and...
8.
Uenaka K, Nakano M, Willis B, Friedrich S, Ferguson-Sells L, Dean R, et al.
Clin Neuropharmacol
. 2011 Dec;
35(1):25-9.
PMID: 22134132
Objectives: Solanezumab is a humanized anti-amyloid β monoclonal antibody being developed as a passive immunization treatment to slow the progression of Alzheimer disease (AD). Pharmacokinetics (PK), pharmacodynamics, safety, and tolerability...
9.
Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H
J Bone Miner Metab
. 2011 Sep;
30(3):326-37.
PMID: 21938381
Teriparatide is an anabolic therapy for osteoporosis approved in the United States since 2002 and European Union since 2003; however, approval in Japan lagged significantly. This report describes analyses based...
10.
Kothare P, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo K, et al.
J Clin Pharmacol
. 2008 Dec;
48(12):1389-99.
PMID: 19047364
In this single-blind, parallel, placebo-controlled study, the pharmacokinetics, pharmacodynamics, tolerability, and safety of subcutaneous exenatide were evaluated in 40 Japanese patients with type 2 diabetes. Patients were allocated to 4...